Published in Clin Cancer Res on September 01, 2005
Micro-NMR for rapid molecular analysis of human tumor samples. Sci Transl Med (2011) 1.96
Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene (2007) 1.77
Large-scale integration of cancer microarray data identifies a robust common cancer signature. BMC Bioinformatics (2007) 1.74
Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology (2008) 1.68
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Biomarker method validation in anticancer drug development. Br J Pharmacol (2007) 1.41
Robust automated tumour segmentation on histological and immunohistochemical tissue images. PLoS One (2011) 1.16
Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise. Nephrol Self Assess Program (2006) 1.11
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med (2007) 1.05
An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis (2014) 0.93
Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol (2008) 0.91
An in vivo platform for tumor biomarker assessment. PLoS One (2011) 0.89
Science behind human saliva. J Nat Sci Biol Med (2011) 0.86
Genomic and oncoproteomic advances in detection and treatment of colorectal cancer. World J Surg Oncol (2009) 0.84
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
The implications of biomarker evidence for systematic reviews. BMC Med Res Methodol (2012) 0.82
Searching for 'omic' biomarkers. Can J Cardiol (2009) 0.80
Quantitative analysis of p53 expression in human normal and cancer tissue microarray with global normalization method. Int J Clin Exp Pathol (2011) 0.79
Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol (2009) 0.78
What will it take to obtain DNA methylation markers for early cervical cancer detection? Gynecol Oncol (2009) 0.78
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
Identifying potential indicators to measure the outcome of translational cancer research: a mixed methods approach. Health Res Policy Syst (2015) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The case for early detection. Nat Rev Cancer (2003) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev (2007) 4.23
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
The genetics and genomics of cancer. Nat Genet (2003) 3.97
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst (2005) 3.62
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst (2003) 3.19
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Protein-folding location can regulate manganese-binding versus copper- or zinc-binding. Nature (2008) 2.81
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol (2010) 2.79
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol (2004) 2.74
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res (2003) 2.61
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol (2009) 2.51
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51